Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in a research note issued to investors on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on ACRS. Jefferies Group LLC set a $36.00 target price on Aclaris Therapeutics and gave the stock a buy rating in a report on Thursday, April 20th. Zacks Investment Research cut Aclaris Therapeutics from a hold rating to a sell rating in a report on Friday, May 12th. ValuEngine cut Aclaris Therapeutics from a hold rating to a sell rating in a report on Tuesday, June 6th. Guggenheim restated a buy rating and issued a $40.00 target price on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Finally, BidaskClub upgraded Aclaris Therapeutics from a hold rating to a buy rating in a report on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Aclaris Therapeutics currently has an average rating of Hold and an average target price of $39.00.

Shares of Aclaris Therapeutics (ACRS) opened at 25.08 on Wednesday. The stock has a 50 day moving average price of $27.77 and a 200 day moving average price of $27.95. Aclaris Therapeutics has a 12 month low of $19.30 and a 12 month high of $33.25. The stock’s market capitalization is $670.54 million.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.12. On average, analysts anticipate that Aclaris Therapeutics will post ($3.10) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/13/aclaris-therapeutics-inc-acrs-given-a-50-00-price-target-by-cantor-fitzgerald-analysts.html.

Several institutional investors have recently modified their holdings of the company. State Street Corp boosted its position in shares of Aclaris Therapeutics by 29.2% in the fourth quarter. State Street Corp now owns 170,630 shares of the biotechnology company’s stock worth $4,631,000 after buying an additional 38,570 shares during the last quarter. Norges Bank acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth $900,000. Teachers Advisors LLC increased its position in shares of Aclaris Therapeutics by 24.9% in the fourth quarter. Teachers Advisors LLC now owns 17,249 shares of the biotechnology company’s stock worth $468,000 after buying an additional 3,435 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth $355,000. Finally, Capital Impact Advisors LLC acquired a new position in shares of Aclaris Therapeutics during the first quarter worth $1,031,000. Institutional investors and hedge funds own 88.64% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.